Abstract: According to some examples, solutions are provided for power distribution of input alternating current (AC) power to at least one power outlet while the input AC power is available, charging of a set of batteries by the input AC power while the input AC power is available, and power distribution of direct current (DC) power from the set of batteries to the power outlet when the input AC power is not available. For such examples, the power outlet is capable of conducting AC power and DC power to a load that is coupled to the power outlet and that can receive either AC power or DC power.

Abstract: Described herein are crystalline forms of Compound 1 useful for the prevention and treatment of angiogenic ocular conditions; methods of treating a disease comprising; processes for preparing; and kits comprising, the same.

Abstract: Described herein are crystalline forms of Compound 1 useful for the prevention and treatment of angiogenic ocular conditions; methods of treating a disease comprising; processes for preparing; and kits comprising, the same.

Abstract: A system and method for identification and location of user identified, feature specific printers works in conjunction with a user's smartphone or tablet computer. A user inputs their desired printer features into their device, and a listing of candidate printers within a search perimeter is rendered. A distance between the user device and each candidate printer is calculated from a determined location user device relative to locations of each of the candidate printers. The user selects their desired printer from the candidates, and directions for the user to walk to the selected printer are generated and displayed.

Abstract: The disclosure provides a bidet washing apparatus equipped with a backflow preventer and methods for using the apparatus for preventing backflow of potentially contaminate water into the bidet washing apparatus. The methods utilizing the apparatus include applying water pressure on a backflow preventer in-line with a reservoir dispenser outlet; and releasing the water pressure on the backflow preventer, thereby allowing air to enter the reservoir dispenser outlet, wherein any contaminated water cannot be pulled back into the apparatus by reduced pressure.

Abstract: Tether clamping assemblies, such as clamping assemblies used to clamp a tether about a spinal feature to assist in spinal fixation, and related methods and systems. In some embodiments, the assembly may comprise a tether configured to engage a bone or other anatomical feature, an inner coupling piece, and an outer coupling piece. A first passage may be at least partially defined by an inner surface of the outer coupling piece and an outer surface of the inner coupling piece. The first passage may be configured such that the tether can be clamped in between the inner surface and the outer surface to allow the tether to move through the first passage in a first direction and apply a force differential such that movement of the tether in a second direction opposite the first direction is made more difficult.

Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

Abstract: Tether clamping assemblies, such as clamping assemblies used to clamp a tether about a spinal feature to assist in spinal fixation, and related methods and systems. In some embodiments, the assembly may comprise a tether configured to engage a bone or other anatomical feature, an inner coupling piece, and an outer coupling piece. A first passage may be at least partially defined by an inner surface of the outer coupling piece and an outer surface of the inner coupling piece. The first passage may be configured such that the tether can be clamped in between the inner surface and the outer surface to allow the tether to move through the first passage in a first direction and lock the tether in place. The inner and outer surfaces preferably differ in surface roughness to facilitate automatic or self-locking of the tether in the assembly.

Abstract: Described herein are crystalline forms of Compound 1 useful for the prevention and treatment of angiogenic ocular conditions; methods of treating a disease comprising; processes for preparing; and kits comprising, the same.

Abstract: Described herein are certain crystalline forms of Compound 3, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.

Abstract: Tether tensioning instruments, such as instruments used to tension and/or lock a tether about a spinal feature to assist in spinal fixation, and related methods and systems. In some embodiments, the instrument may comprise a handle, a tensioner base coupled with the handle, at least a portion thereof being movably coupled to the handle, and a tether coupling member coupled with the tensioner base and configured to fixedly engage a tether. The instrument may further comprise a tensioner tip movably coupled with the tensioner base, wherein at least a portion of the tensioner base is biased away from the tensioner tip, and wherein the instrument is configured to allow for step-wise movement of the tensioner tip away from the tensioner base to increase tension between the tether and an element of the spinal fixation system.

Abstract: Provided herein is a compound, 1-(4-(3-amino-[1,2,3]triazolo[1,5-a]pyridin-4-yl)phenyl)-3-(3-chlorophenyl)urea, pharmaceutical compositions thereof, and crystal forms thereof. Also provided are particles (e.g., nanoparticles) comprising the compound, and pharmaceutical compositions thereof, that are mucus penetrating. Also provided herein are methods and kits for using the compound, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.

Abstract: A calling user initiates a telephonic communication with a receiving user by dialing a phone number of the receiving user in his or her address book. The communication is transmitted from the calling user's device to the receiving user's device through a network that is not using Internet protocol or Internet-based, e.g., Transmission Control Protocol (TCP), Internet Protocol (IP), TCP-IP, or Voice over Internet Protocol (VoIP). After a number of notifications has passed on the receiving user's device and the receiving user is not able to answer the telephonic communication, a local voicemail recorder will be activated to record and store the telephonic communication for later retrieval by the receiving user. The stored communication is identifier by a sequence of string containing at least one of a name, a telephone number, a storage location, a date-time attribute, and a duration associated with the stored communication.

Abstract: In one example, a system for bypass switch control includes a controller coupled to a number of backup power modules and to a number of bypass switches that correspond to each of the number of backup power modules, wherein the controller activates a bypass switch when a corresponding backup power module is deactivated.

Abstract: In one example, a system for parallel output of backup power modules includes a first backup power module coupled to an input and a first output of an enclosure, a second backup power module coupled to the input and a second output of the enclosure, wherein the second backup power module is coupled in parallel with the first backup power module, and a switch coupling the first backup power module and the first output of the enclosure to the second output of the enclosure.

Abstract: Example implementations relate to concurrent alternating-current and direct-current. In one example, a device comprises a power module connected to a first power outlet, the power module connected to a second power outlet, and a controller to the power module to concurrently provide alternating-current (AC) power to the first power outlet and direct-current (DC) power to the second power outlet by switching a transistor including switching circuitry in response to an absence of AC input power to the device.

Abstract: Provided herein is a compound, 1-(4-(3-amino-[1,2,3]triazolo[1,5-a]pyridin-4-yl)phenyl)-3-(3-chlorophenyl)urea, pharmaceutical compositions thereof, and crystal forms thereof. Also provided are particles (e.g., nanoparticles) comprising the compound, and pharmaceutical compositions thereof, that are mucus penetrating. Also provided herein are methods and kits for using the compound, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.